Your activity: 48 p.v.
< Back
your limit has been reached. plz Donate us to allow your ip full access, Email: sshnevis@outlook.com

Effect of primary tumor location on survival times of RAS wild-type metastatic colorectal cancer with and without first-line cetuximab

Effect of primary tumor location on survival times of RAS wild-type metastatic colorectal cancer with and without first-line cetuximab
Study Treatment Median PFS (months) Median OS (months)
Left Right Left Right
FIRE-3[1] FOLFIRI + cetuximab 10.7 7.6 38.3 18.3
FOLFIRI + bevacizumab 10.7 9 28 23
CRYSTAL[1] FOLFIRI + cetuximab 12.0 8.1 28.7 18.5
FOLFIRI 8.9 7.1 21.7 15.0
CALGB 80405[2] FOLFOX/FOLFIRI + cetuximab     39.3 13.6
FOLFOX/FOLFIRI + bevacizumab     32.6 29.2
PFS: progression-free survival; OS: overall survival; FOLFIRI: irinotecan plus leucovorin and short-term infusional fluorouracil; CALGB: Cancer and Leukemia Group B; FOLFOX: oxaliplatin plus leucovorin and short-term infusional fluorouracil.
References:
  1. Tejpar S, Stintzing S, Ciardiello F, et al. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. JAMA Oncol 2016.
  2. Venook AP, Niedzwiecki D, Innocenti F, et al. Impact of primary (1ยบ) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol 2016; 34:(suppl; abstr 3504).
Graphic 114601 Version 1.0